Next |
home / stock / rprx / rprx message board
Subject | By | Source | When |
---|---|---|---|
$RPRX Royalty Pharma PLC | mick | investorshub | 04/30/2023 9:29:51 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 04/15/2023 3:47:49 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 02/27/2023 1:08:22 AM |
$RPRX Royalty Pharma PLC | mick | investorshub | 02/21/2023 11:47:48 PM |
Repros Therapeutics Inc. | mick | investorshub | 02/21/2023 11:47:29 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 02/05/2023 11:15:41 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 12/18/2022 10:32:06 PM |
whytestocks: $RPRX News Article - Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran Fro | whytestocks | investorshangout | 11/09/2022 7:45:50 PM |
whytestocks: $RPRX News Article - Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma fo | whytestocks | investorshangout | 11/09/2022 6:35:50 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 10/23/2022 5:40:01 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 08/31/2022 10:18:11 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 07/17/2022 10:18:35 PM |
whytestocks: $RPRX News Article - Royalty Pharma to Announce Second Quarter 2022 Financial Results o | whytestocks | investorshangout | 07/14/2022 2:45:53 PM |
$RPRX Royalty Pharma PLC | mick | investorshub | 06/22/2022 12:30:08 AM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 06/04/2022 7:11:43 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 05/01/2022 5:54:03 PM |
https://www.otcmarkets.com/stock/$RPRX | mick | investorshub | 03/12/2022 9:19:13 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 03/12/2022 7:21:14 PM |
Royalty Pharma PLC ($RPRX) | mick | investorshub | 02/05/2022 10:44:02 PM |
https://www.otcmarkets.com/stock/$RPRX | mick | investorshub | 01/02/2022 10:13:39 PM |
News, Short Squeeze, Breakout and More Instantly...
Royalty Pharma (NASDAQ: RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This co...
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 202...
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases...